drugset / Trial / NCT00883194

A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers

NCT00883194

Phase 1/2 Completed 15 enrolled PainReform LTD
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.

Timeline

Start
2010-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PRF-108 Unknown 4 %
Subject Ropivacaine Other / unclassified 0.5 %
Subject Ropivacaine Other / unclassified 4 %

Indications

No indication recorded.